Please use this identifier to cite or link to this item:
|Title:||Alginate hydrogel improves anti-angiogenic bevacizumab activity in cancer therapy|
|Author(s):||Ferreira, Natália N.|
Ferreira, Leonardo M.B.
Reis, R. M.
Seraphim, Thiago V.
Borges, Júlio César
Gremião, Maria Palmira D.
|Keywords:||Protein delivery system|
Calcium alginate hydrogel
|Journal:||European Journal of Pharmaceutics and Biopharmaceutics|
|Citation:||Ferreira, N. N., Ferreira, L. M., Miranda-Gonçalves, V., Reis, R. M., Seraphim, T. V., Borges, J. C., ... & Gremião, M. P. D. (2017). Alginate hydrogel improves anti-angiogenic bevacizumab activity in cancer therapy. European Journal of Pharmaceutics and Biopharmaceutics, 119, 271-282|
|Abstract(s):||Anti-vascular endothelial growth factor (anti-VEGF) therapy applied to solid tumors is a promising strategy, yet, the challenge to deliver these agents at high drug concentrations together with the maintenance of therapeutic doses locally, at the tumor site, minimizes its benefits. To overcome these obstacles, we propose the development of a bevacizumab-loaded alginate hydrogel by electrostatic interactions to design a delivery system for controlled and anti-angiogenic therapy under tumor microenvironrnental conditions. The tridimensional hydrogel structure produced provides drug stability and a system able to be introduced as a flowable solution, stablishing a depot after local administration. Biological performance by the chick embryo chorioallantoic membrane (CAM) assay indicated a pH-independent improved anti-angiogenic activity (similar to 50%) compared to commercial available anti-VEGF drug. Moreover, there was a considerable regression in tumor size when treated with this system. Immunohistochemistry highlighted a reduced number and disorganization of microscopic blood vessels resulting from applied therapy. These results suggest that the developed hydrogel is a promising approach to create an innovative delivery system.that offers the possibility to treat different solid tumors by intratumoral administration.|
|Description:||Alginate hydrogel improves anti-angiogenic bevacizumab activity in cancer therapy|
|Appears in Collections:||ICVS - Artigos em Revistas Internacionais com Referee|